A study has discovered that men using testosterone therapy or TTh and statins concomitantly seems to have lower odds of developing high-grade and advance stage prostate cancer, and this benefit is especially pronounced among White and Black men.
 |
| Photo: Male Patient with Medical Professional | InStyleHealth |
Research analysis covered 74,181 White, 9,157 Black,
and 3,313 Hispanic men diagnosed with prostate cancer. Experts determined pre-diagnostic
prescription of TTh and statins. Weighted multivariable-adjusted conditional
logistic and Cox proportional hazards models were used to assess the concurrent
use of the two medications in relation to the incidence of prostate cancer.
The incidence of prostate cancer was inversely
correlated with either TTh or statins. Similar findings were observed for
high-grade and advanced prostate cancer.
Using testosterone therapy and statins simultaneously,
revealed a greater protection against the incidence of prostate cancer, as well
as high-grade and advanced disease. The correlations remained significant among
White and Black men only. For the Hispanic men, statins were correlated with
prostate cancer-specific mortality.
Current data recommends a potential interaction
between TTh and statin, with an additive effect on incident and aggressive
prostate cancer in men of different racial and ethnicity. Further studies are required
to establish the independent inverse correlation of TTh and the joint inverse
correlation of TTh plus statins on the risk of prostate cancer in understudied
populations, according to experts.
Source: Cancer Prev Res
2021;doi:10.1158/1940-6207.CAPR-21-0040